



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of)
HOKE et al.) Group Art Unit: TBA
Serial No.: 10/757,468) Examiner: TBA
Filed: January 15, 2004) Atty. Dkt. No.: 114122-00162
For: PARTIALLY DOUBLE)
STRANDED NUCLEIC ACIDS)
METHODS OF MAKING)
AND USE THEREOF)

**REPLY TO NOTICE TO COMPLY WITH REQUIREMENT FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Commissioner of Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

This Reply is filed in response to the Notice to Comply mailed August 12, 2004.

Pursuant to 37 C.F.R. 1.821(e), Applicant respectfully requests that the sequence listing in computer readable form from U.S. Patent Application No. 09/984,517 ("the '517 Application") be used for the present application in lieu of a new computer readable form. The contents of the Sequence Listing of the present application and the computer readable form of the '517 Application are the identical and contain no new matter as required by 37 C.F.R. 1.821(e); 1.821(f), 1.821(g), 1.825(b) or 1.825(d). Further, the computer readable form of '517 Application is on file with the U.S. Patent and Trademark Office and complies with all sections of 37 C.F.R. 1.821.

Applicant has responded to the Notice to Comply mailed August 12, 2004.

In the event there are any questions relating to this Reply or to the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney concerning such questions so that the prosecution of this application may be expedited.


Should the petition and/or fee due in connection with this submission be deficient or missing, the Office is hereby authorized to charge any shortage or credit any overpayment of fees to BLANK ROME LLP, Deposit Account No. 23-2185 (114122-00162). In the event that a petition for an extension of time is required to be submitted herewith and in the event that a separate petition does not accompany this response, applicant hereby petitions under 37 C.F.R. 1.136(a) for an extension of time for as many months as are required to render this submission timely.

Any fees due are authorized above.

Respectfully submitted,


Date: December 13, 2004

By:



Brian C. Jones
Registration No. 37,857

BLANK ROME LLP
Watergate
600 New Hampshire Avenue
Washington, DC 20037
Telephone: 202-772-5800
Facsimile: 202- 572-1400



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/757,468	01/15/2004	Glenn Hoke	114122-00148

CONFIRMATION NO. 5043

27557

BLANK ROME LLP

600 NEW HAMPSHIRE AVENUE, N.W.

WASHINGTON, DC 20037

FORMALITIES LETTER



OC000000013521754

Date Mailed: 08/12/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents

P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in dark ink, appearing to be 'Munich', is written over a horizontal line.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE